Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Pharmaform launches nanoparticle engineering drug delivery technology at AAPS 2008

Abstract:
Evaporative Precipitation into Aqueous Solution particle engineering technology dramatically improves drug solubility and enhances bioavailability

Pharmaform launches nanoparticle engineering drug delivery technology at AAPS 2008

Austin, TX | Posted on November 17th, 2008

PharmaForm, a pharmaceutical product development, manufacturing and analytical testing services company, today announced the launch of its new Evaporative Precipitation into Aqueous Solution (EPAS) drug delivery technology at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, November 16 through 20, 2008, Georgia World Congress Center, Atlanta, Georgia. PharmaForm will showcase the EPAS technology at booth #2813.

EPAS is a particle engineering technology that produces nanostructured particles with properties of high surface areas, rapid dissolution, improved physical stability, and exceptional bioavailability when compared to conventional formulation technologies. It is designed to transform poorly water-soluble drugs into stable nanoparticles, without physical milling or grinding procedures.

EPAS is applicable to a wide range of hydrophobic molecules and can be applied to a variety of dosage forms, including solid oral, liquid, pulmonary and transdermal. Companies can utilize EPAS to improve the bioavailability of poorly soluble new chemical entities (NCEs) or to improve upon existing formulations to extend patent life and product life cycle.

"The benefits of improved patient compliance and clinical profiles, reduced dose variability, and a readily scalable process provide companies with a patentable drug delivery technology for their development pipeline," said Michael Crowley, Ph.D. vice president of business development at PharmaForm. "EPAS is a powerful strategy for companies to capitalize on the full potential of their highly effective yet poorly soluble compounds."

The EPAS platform is fast, continuous, and scalable using conventional equipment which can be directly incorporated into an uninterrupted manufacturing process. The EPAS process eliminates concerns of particle contamination and reduces the degree of crystallinity compared to milling techniques. The process produces highly stable crystalline drug particles with low levels of residual solvents using GRAS approved excipients.

"Compared to physical methods of micronization, such as wet-milling, EPAS engineered particles demonstrate a very narrow particle size range, do not agglomerate and exhibit improved flow," said Jason Vaughn, Ph.D., vice president of operations at PharmaForm. "The added benefit of eliminating the concern for particle contamination observed with milling techniques facilitates high yield and efficient system validation, ensuring a smoother path towards clinical and commercial manufacturing."

For further information on PharmaForm's EPAS technology or drug development services, visit booth #2813 at AAPS, Georgia World Congress Center, Atlanta, GA, USA or visit www.pharmaform.com, e-mail or call (512) 834-0449.



About EPAS

EPAS particle engineering technology uses evaporative precipitation to generate nanostructured drug particles exhibiting rapid dissolution rates and enhanced bioavailability. The process involves dissolving the active in non-aqueous solvent followed by precipitation into an aqueous solution. The rapid expansion and atomization of the solvent in the water phase causes the formation of drug particles ranging in size from nanometer scale to micron scale, which are then stabilized using GRAS excipients. The evaporated solvent is recovered, and the stabilized particles isolated from the aqueous phase by standard techniques.

####

About PharmaForm
Since 1996, PharmaForm has built an international reputation for delivering novel and innovative solutions to challenging problems in pharmaceutical product development, manufacturing, and analytical services. We have formulation expertise in oral, nasal, pulmonary, dermal, mucosal and vaginal delivery. Our scientific staff has considerable experience in drug delivery including time-release formulations, solubility enhancement and hot-melt extrusion techniques. PharmaForm's state-of-the-art facility is registered with the FDA and the DEA and is cGMP/GLP compliant. Our expertise. Your advantage.



About AAPS



Founded in 1986, the American Association of Pharmaceutical Scientists is a scientific society focused on the pharmaceutical industry. It's the proud product of a core group of scientists who banded together to create a society tailored to their own specific professional and business needs. Today, AAPS' mission is to provide a dynamic international forum for the exchange of knowledge among scientists to enhance their contributions to health. AAPS offers timely scientific programs, on-going education, opportunities for networking, and professional development to its members. For more information, visit www.aaps.org.

For more information, please click here

Contacts:
Elizabeth Hickman
PharmaForm, LLC.
(512) 834-0449 x264

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

University of Manchester selects Anasys AFM-IR for coatings and corrosion research July 30th, 2014

Nature inspires a greener way to make colorful plastics July 30th, 2014

Analytical solutions from Malvern Instruments support University of Wisconsin-Milwaukee researchers in understanding environmental effects of nanomaterials July 30th, 2014

FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014

Nanomedicine

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

New imaging agent provides better picture of the gut July 25th, 2014

Announcements

University of Manchester selects Anasys AFM-IR for coatings and corrosion research July 30th, 2014

Nature inspires a greener way to make colorful plastics July 30th, 2014

Analytical solutions from Malvern Instruments support University of Wisconsin-Milwaukee researchers in understanding environmental effects of nanomaterials July 30th, 2014

FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE